Literature DB >> 8694531

Application of 31P NMR spectroscopy in clinical analysis of changes of serum phospholipids in leukemia, lymphoma and some other non-haematological cancers.

M Kuliszkiewicz-Janus1, W Janus, S Baczyński.   

Abstract

The sodium salt of cholic acid added to serum caused separation of three phospholipid peaks located upfield from inorganic phosphate (Pi) due to phosphatidylethanolamine with sphingomyelin (PE + SM), lysophosphatidylcholine (LPC), and phosphatidylcholine (PC). 31P NMR spectra were obtained from the sera of 15 healthy volunteers, 10 individuals suffering from acute leukemia, 4 persons with malignant lymphomas, 13 patients with digestive tract tumors and 5 with renal cell carcinoma. The present studies confirmed our previous observation that the 31P spectra of sera of patients with acute leukemia and malignant lymphomas revealed a significant decrease in the phospholipid level at the time of diagnosis and displayed a good correlation between spectral parameters and stage of disease in patients responding and non-responding to therapy. Contrary to the preliminary studies, peaks from PE + SM and PC, and also a peak from LPC were observed. Changes in phospholipids in the 31P NMR spectra observed in patients suffering from digestive tract tumors and renal cell carcinoma were primarily dependent on the advance of the disease. Most of our patients with these cancers were in the early stage of the disease, and the spectra showed statistically significant decrease only in the LPC peak area, and no statistically significant changes of peak areas of PC and PE+SM in comparison to the control group. In conclusion, we can state that the LPC peak area is the most sensitive indicator in the monitoring of treatment in acute leukemia and malignant lymphomas. Our results also showed that LPC peak areas were decreased in the early stages of digestive tract tumors and a renal cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8694531

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  12 in total

1.  Aberrations in plasma phospholipid fatty acids in lung cancer patients.

Authors:  Rachel A Murphy; Taylor F Bureyko; Marina Mourtzakis; Quincy S Chu; M Thomas Clandinin; Tony Reiman; Vera C Mazurak
Journal:  Lipids       Date:  2011-12-10       Impact factor: 1.880

2.  Low level of high-density lipoprotein cholesterol correlates with poor prognosis in extranodal natural killer/T cell lymphoma.

Authors:  Liang Wang; Pei-dong Chi; Hao Chen; Jin Xiang; Zhong-jun Xia; Yu-jing Zhang
Journal:  Tumour Biol       Date:  2014-03

3.  Systemic alterations in concentrations and distribution of plasma phospholipids in prostate cancer patients.

Authors:  B Cvetković; V Vučić; Z Cvetković; T Popović; M Glibetić
Journal:  Med Oncol       Date:  2011-03-26       Impact factor: 3.064

4.  Metabonomics identifies serum metabolite markers of colorectal cancer.

Authors:  Binbin Tan; Yunping Qiu; Xia Zou; Tianlu Chen; Guoxiang Xie; Yu Cheng; Taotao Dong; Linjing Zhao; Bo Feng; Xiaofang Hu; Lisa X Xu; Aihua Zhao; Menghui Zhang; Guoxiang Cai; Sanjun Cai; Zhanxiang Zhou; Minhua Zheng; Yan Zhang; Wei Jia
Journal:  J Proteome Res       Date:  2013-05-29       Impact factor: 4.466

5.  Marine phospholipids--a promising new dietary approach to tumor-associated weight loss.

Authors:  Lenka A Taylor; Lars Pletschen; Jann Arends; Clemens Unger; Ulrich Massing
Journal:  Support Care Cancer       Date:  2009-04-29       Impact factor: 3.603

6.  Measurement of endogenous lysophosphatidic acid by ESI-MS/MS in plasma samples requires pre-separation of lysophosphatidylcholine.

Authors:  Zhenwen Zhao; Yan Xu
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-08-27       Impact factor: 3.205

7.  Saturated and mono-unsaturated lysophosphatidylcholine metabolism in tumour cells: a potential therapeutic target for preventing metastases.

Authors:  Anna Raynor; Peter Jantscheff; Thomas Ross; Martin Schlesinger; Maurice Wilde; Sina Haasis; Tim Dreckmann; Gerd Bendas; Ulrich Massing
Journal:  Lipids Health Dis       Date:  2015-07-11       Impact factor: 3.876

8.  Lysophosphatidylcholine inhibits membrane-associated SNARE complex disassembly.

Authors:  Leah Shin; Sunxi Wang; Jin-Sook Lee; Amanda Flack; Guangzhao Mao; Bhanu P Jena
Journal:  J Cell Mol Med       Date:  2012-08       Impact factor: 5.310

9.  In Vitro and In Vivo (1)H-MR Spectroscopic Examination of the Renal Cell Carcinoma.

Authors:  F Süllentrop; J Hahn; D Moka
Journal:  Int J Biomed Sci       Date:  2012-06

10.  Plasma lyso-phosphatidylcholine concentration is decreased in cancer patients with weight loss and activated inflammatory status.

Authors:  Lenka A Taylor; Jann Arends; Arwen K Hodina; Clemens Unger; Ulrich Massing
Journal:  Lipids Health Dis       Date:  2007-07-10       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.